CompletedNCT02164981
Sodium Nitroprusside Compared With Placebo for Schizophrenia Symptoms
About this title
Read the official source — NCT02164981Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Boston and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 1, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02164981
- Official title
Show the full official title
A Randomized Double-Blind, Placebo-Controlled, Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston · Worcester · Glen Oaks
1 more locations
- New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including sodium nitroprusside.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
